Завершено
Фаза III
Россия
Placebo; Belimumab 1 mg/kg; Belimumab 10 mg/kg · Human Genome Sciences Inc.
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)